DCM
PTGX icon

Driehaus Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Driehaus Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76M Sell
720,928
-378,242
-34% -$33.5M 0.56% 44
2025
Q4 		$96M Sell
1,099,170
-40,684
-4% -$3.33M 0.65% 35
2025
Q3 		$75.7M Buy
1,139,854
+382,144
+50% +$21.7M 0.54% 54
2025
Q2 		$41.9M Buy
757,710
+522,637
+222% +$25.1M 0.34% 99
2025
Q1 		$11.4M Sell
235,073
-104,625
-31% -$4.38M 0.11% 227
2024
Q4 		$13.1M Sell
339,698
-105,654
-24% -$4.61M 0.11% 217
2024
Q3 		$20M Sell
445,352
-111,483
-20% -$4.5M 0.17% 171
2024
Q2 		$19.3M Sell
556,835
-3,695
-0.7% -$108K 0.19% 149
2024
Q1 		$16.2M Buy
560,530
+361,841
+182% +$9.85M 0.16% 187
2023
Q4 		$4.56M Buy
+198,689
New +$3.48M 0.05% 270

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Driehaus Capital Management's PTGX Position: Q1 2026 in Review

Driehaus Capital Management reduced its Protagonist Therapeutics (PTGX) stake by 34% in Q1 2026, selling an estimated $33.5M and leaving 720,928 shares worth $76M. The position accounts for 0.56% of the portfolio, ranked #44.

Driehaus Capital Management first reported a position in PTGX in Q4 2023 and has held it in 10 quarters since. The position peaked at $96M in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Driehaus Capital Management held 720,928 shares of Protagonist Therapeutics worth $76M as of Q1 2026.
  • Driehaus Capital Management sold 378,242 Protagonist Therapeutics shares in Q1 2026, an estimated $33.5M.
  • Protagonist Therapeutics made up 0.56% of Driehaus Capital Management's portfolio in Q1 2026, its #44 holding.
  • Driehaus Capital Management first reported a position in Protagonist Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Driehaus Capital Management's Protagonist Therapeutics position peaked at $96M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.